Drug Trial Radar · NCT00531479
Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis
Last checked: Nov 19, 2026Latest source record: Apr 30, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
459
Actual
Start
Jul 2008
Primary completion
Apr 2011
Study completion May 2011
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 18, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compares the effectiveness and safety of the combination of anidulafungin and voriconazole compared to that of voriconazole alone (which is generally considered the standard of care) for the treatment of Invasive Aspergillosis.
Conditions
- Aspergillosis
Interventions
voriconazoleDrug
First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV BID plus anidulafungin placebo IV qd. Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin placebo IV qd. Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin placebo IV qd, OR Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy. Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.
anidulafunginDrug
First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter. Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd. Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd, OR Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy. Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.
voriconazoleDrug
First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter. Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd. Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd, OR Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy. Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause Mortality at Week 6 in Participants With Proven or Probable Invasive AspergillosisTime frame: Day 1 to Day 42 (Week 6)
Locations
107 sites in 24 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Little Rock, Arkansas
Pfizer Investigational Site
La Jolla, California
Pfizer Investigational Site
La Jolla, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
San Francisco, California
Pfizer Investigational Site
Gainesville, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Atlanta, Georgia
Pfizer Investigational Site
Chicago, Illinois
Pfizer Investigational Site
Chicago, Illinois
Pfizer Investigational Site
Baltimore, Maryland
Pfizer Investigational Site
Baltimore, Maryland
Pfizer Investigational Site
Baltimore, Maryland
Pfizer Investigational Site
Baltimore, Maryland
Pfizer Investigational Site
Detroit, Michigan
Pfizer Investigational Site
Detroit, Michigan
Pfizer Investigational Site
Rochester, New York
Pfizer Investigational Site
Chapel Hill, North Carolina
Pfizer Investigational Site
Winston-Salem, North Carolina
Pfizer Investigational Site
Portland, Oregon
Pfizer Investigational Site
Philadelphia, Pennsylvania
Pfizer Investigational Site
Houston, Texas
Pfizer Investigational Site
Seattle, Washington
Pfizer Investigational Site
Seattle, Washington
Pfizer Investigational Site
Westmead, New South Wales, Australia
Pfizer Investigational Site
Herston, Queensland, Australia
Pfizer Investigational Site
Adelaide, South Australia, Australia
Pfizer Investigational Site
Bruges, Belgium
Pfizer Investigational Site
Brussels, Belgium
Pfizer Investigational Site
Leuven, Belgium
Pfizer Investigational Site
Yvoir, Belgium
Pfizer Investigational Site
Curitiba, Paraná, Brazil
Pfizer Investigational Site
Rio de Janeiro, Rio de Janeiro, Brazil
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
Hamilton, Ontario, Canada
Pfizer Investigational Site
Hamilton, Ontario, Canada
Showing 40 of 107 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.